Lonza has reported strong growth in the first quarter of 2015. The company met its targets in both the speciality ingredients and pharma sectors. Mid-term guidance also suggests positive development in both sectors leading up to 2018.
Despite foreign exchange rate and raw material volatility, Lonza plans for growth of at least 5% as a result of portfolio optimisation and productivity improvements.
Richard Ridinger, CEO of Lonza, said: “Our first quarter results demonstrate that we are well-positioned to deliver on our 2015 targets. We’re expecting positive performance and further growth throughout the rest of the year and in the foreseeable future. Our solid business plans in our well-defined markets and associated clear strategic direction allow us to provide a positive mid-term outlook until 2018.”
